



# MANGALAM DRUGS & ORGANICS LTD.

## A. Un- Audited Financial Results(Provisional) for the Quarter and Half Year ended 30th September 2014

(Rs. in Lacs)

Sr. No.	Particulars	Unaudited			Unaudited		Audited
		Quarter ended		Corresponding 3 months ended in the previous period	Half year ended		Year Ended
		3 months ended	3 months ended		Year to date figures for Current period ended	Year to date figures for the previous period ended	Previous accounting year ended
		30.09.14	30.06.14	30.09.13	30.09.14	30.09.13	31.03.14
1	Sales/Income from operation(Net of Excise duty)	4084.93	3855.81	2812.68	7940.74	4648.15	12231.97
2	Other Operating Income	264.97	7.74	8.61	272.71	17.54	35.78
3	Total Net Income from Operation	4349.90	3863.55	2821.29	8213.45	4665.69	12267.75
4	Expenditure						
	(a) Increase / decrease in stock in trade & work in progress	1050.87	(152.16)	(116.08)	898.71	(501.07)	(544.63)
	(b) Consumption of raw materials	1698.64	2765.71	1788.18	4464.35	3574.73	8374.88
	(c) Employee Benefits	275.09	253.18	266.80	528.27	511.07	1024.55
	(d) Depreciation	93.63	106.90	98.79	200.53	197.28	401.05
	(e) Other expenditure	745.16	641.06	630.38	1386.22	1092.14	2436.55
	(f) Total	3863.39	3614.69	2668.07	7478.08	4874.15	11692.40
5	Profit(+)/Loss(-) from operations before Other income,Finance cost and Exceptional Items(3-4)	486.51	248.86	153.22	735.37	(208.46)	575.35
6	Other income	2.69	2.19	0.00	4.88	1.98	8.23
7	Profit (+) / Loss (-) from ordinary activities before Finance Cost & Exceptional Items(5+6)	489.20	251.05	153.22	740.25	(206.48)	583.58
8	Finance Cost	273.64	271.35	250.13	544.99	476.99	974.21
9	Profit(+)/Loss(-) from ordinary activities after Finance cost but before Exceptional Items(7-8)	215.56	(20.30)	(96.91)	195.26	(683.47)	(390.63)
10	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
11	Profit(+)/Loss(-) before Tax (9-10)	215.56	(20.30)	(96.91)	195.26	(683.47)	(390.63)
12	Tax Expenses(incl Deferred Tax)	15.00	0.00	0.00	15.00	0.00	(86.71)
13	Net Profit(+)/Loss(-) after Tax (11-12)	200.56	(20.30)	(96.91)	180.26	(683.47)	(303.92)
14	Extraordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
15	Net Profit(+)/Loss(-) for the period(13-14)	200.56	(20.30)	(96.91)	180.26	(683.47)	(303.92)
16	Paid up Equity Share Capital (face value Rs.10/-each)	1317.82	1317.82	1317.82	1317.82	1317.82	1317.82
12	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year.	0.00	0.00	0.00	0.00	0.00	1004.48
13	Earning per share (EPS)						
	(a) Basic and diluted EPS before extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	1.52	(0.15)	(0.74)	1.37	(5.19)	(2.31)
	(b) Basic and diluted EPS after extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	1.52	(0.15)	(0.74)	1.37	(5.19)	(2.31)
14	Non Promoters Shareholding						
	- Number of shares	7628115	7628115	7548453	7628115	7548453	7628115
	- Percentage of shareholding	57.88	57.88	57.28	57.88	57.28	57.88
15	Promoters and Promoter group Shareholding						
	a) Pledged/ Encumbered						
	Number of Shares	5491228	5491228	5448708	5491228	5448708	5491228
	Percentage of Shares (as a % of the total shareholding of promoter & promoter group)	98.94	98.94	96.78	98.94	96.78	98.94
	Percentage of Shares (as a % of the total share capital of the company)	41.67	41.67	41.35	41.67	41.35	41.67
	b) Non-encumbered						
	Number of Shares	58905	58905	181087	58905	181087	58905
	Percentage of Shares (as a % of the total shareholding of promoter & promoter group)	1.06	1.06	3.22	1.06	3.22	1.06
	Percentage of Shares (as a % of the total share capital of the company)	0.45	0.45	1.37	0.45	1.37	0.45
16	Investors Complaints:	3 Months ended 30.09.14					
	Pending at the Beginning of the Quarter	Nil					
	Received during the Quarter	Nil					
	Disposed of during the Quarter	Nil					
	Remaining unresolved at the end of the Quarter	Nil					

### Notes:

- The above results have been reviewed by the Audit Committee and thereafter, were taken on record by the Board of Directors of the Company at their meeting held on 14th, November 2014.
- As the Company's business activity falls within a single primary business segment viz "Manufacturing of Bulk Drugs" the disclosure requirements of Accounting Standard(AS-17)"Segment Reporting" is not applicable.
- Previous year figure are regrouped wherever necessary.

On behalf of Board of Directors  
For Mangalam Drugs & Organics Ltd

Place: Mumbai  
Date: 11.12.2014

Chairman  
(Shri Govardhan M.Dhoot)